Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01392521 |
| Title | Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Bayer |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | NLD | DEU |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Scottsdale | Arizona | 85260 | United States | Details | ||
| Las Vegas | Nevada | 89169 | United States | Details | ||
| Greenville | South Carolina | 29605 | United States | Details | ||
| Houston | Texas | 77030 | United States | Details | ||
| Tyler | Texas | 75702 | United States | Details | ||
| Vancouver | Washington | 98684 | United States | Details | ||
| Freiburg | Baden-Württemberg | 79106 | Germany | Details | ||
| Rotterdam | 3015 CE | Netherlands | Details |